NASDAQ
Adaptive Biotechnologies Corporation (ADPT) has a consensus Buy rating from 17 analysts with an average price target of $21.33, representing +27.1% upside from the current price of $16.78.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Feb 6, 2026 | Unknown | BTIG | $22.00 | $16.47 | +33.58% |
| Feb 6, 2026 | Sebastian Sandler | Piper Sandler | $21.00 | $16.47 | +27.50% |
| Jan 26, 2026 | Unknown | Guggenheim | $21.00 | $18.91 | +11.05% |
| Dec 1, 2025 | Kallum Titchmarsh | Morgan Stanley | $21.00 | $18.84 |
May 12, 2026 | Maintained | Morgan Stanley | Equal Weight | Equal Weight |
May 6, 2026 | Maintained | Guggenheim | Buy | Buy |
May 6, 2026 | Maintained | JP Morgan | Overweight | Overweight |
May 6, 2026 | Maintained | TD Cowen | Buy | Buy |
May 6, 2026 | Maintained | BTIG | Buy | Buy |
| +11.46% |
| Oct 15, 2025 | Unknown | Piper Sandler | $20.00 | $16.28 | +22.85% |
No price data available for this timeframe.